公募基金方面，本期较上一期持股增加的公募基金共计4个，包括华夏国证疫苗与生物科技指数发起式 A、国泰创业板医药卫生ETF、招商中证疫苗与生物技术ETF、富国国证疫苗与生物科技ETF，持股增 加占比小幅上涨。本期较上一季度持股减少的公募基金共计6个，主要包括易方达创业板ETF、招商国 证生物医药指数A、南方中证500ETF、嘉实中证疫苗与生物技术ETF、生物疫苗ETF等，持股减少占比 达0.66%。本期较上一季未再披露的公募基金共计204个，主要包括创新药、天弘国证生物医药ETF、国 泰中证生物医药ETF、广发创新药ETF、广发创业板ETF等。 2025年10月29日，沃森生物(300142.SZ)发布2025年第三季报。截至2025年10月28日，共有12个机构投 资者披露持有沃森生物A股股份，合计持股量达1.28亿股，占沃森生物总股本的8.00%。其中，前十大 机构投资者包括中国工商银行股份有限公司-易方达创业板交易型开放式指数证券投资基金、成都喜云 企业管理合伙企业(有限合伙)、中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金、 中国银行股份有限公司-招商国证生物医药指数分级证券投资基金、 ...

Group 1 - The core viewpoint is that the national medical insurance fund in China is operating safely and steadily in 2024, with a coverage rate stable at over 95% and total income and expenditure both showing year-on-year growth, resulting in a cumulative surplus of 5.31 trillion yuan [1] - The number of employees covered by medical insurance increased by 2.3% year-on-year, with income growing by 3.5% and expenditure rising by 7.6%. The overall fund income increased by 4.6%, while expenditure surged by 13.5%, leading to a surplus of 41.2 billion yuan for the current period [1] - The income from resident medical insurance grew by 5.78%, with expenditure increasing by 1.9%, resulting in a surplus of 51.9 billion yuan for the current period. The overall operation of the medical insurance fund remains stable, providing a solid payment environment for the biopharmaceutical industry [1] Group 2 - The Vaccine ETF tracks the National Index of Vaccines and Biotechnology, which is compiled by Shenzhen Securities Information Co., Ltd. It selects listed companies involved in vaccine research, production, and related biotechnology sectors from the A-share market to reflect the overall performance of these securities [1] - This index focuses on the biopharmaceutical industry, particularly companies in the vaccine segment, effectively tracking the comprehensive trends of this specialized market [1] - Investors without stock accounts can consider the Guotai National Vaccine and Biotechnology ETF Initiated Link A (017185) and Guotai National Vaccine and Biotechnology ETF Initiated Link C (017186) [1]